New Drug Updates: GSK Announces Positive Results from anti-BCMA Immune Conjugate Trial

On August 23, GlaxoSmithKline announced positive headline results for the DREAMM-2 randomized trial with two doses of GSK2857916 (belantamab mafodotin or “Bela”), an anti-BCMA monoclonal antibody drug conjugate. (View IMF video about belantamab mafodotin, filmed at ASCO 2019.) Exact responses and outcomes were not disclosed, but excellent results were previously reported. Safety and tolerability were acceptable, as noted in the earlier DREAMM-1 exploratory study. 

Real Food: Critically Important for the World’s Health

I have written a lot about the benefits of “real food,” especially as part of a Mediterranean-style diet. A large new study reaffirms the benefits of a Mediterranean diet and links the global burden of disease to a poor diet.

Remembering a myeloma patient advocate extraordinaire

With great sorrow we announce the passing of Aldo Del Col, M.S.M., Co-Founder of Myeloma Canada and International Myeloma Foundation Board of Directors Member.

New Focus on Resilience

This past weekend the IMF convened the 20th annual Support Group Leaders Summit in Dallas, Texas. As usual, this was a highly emotional and successful event, bringing together 69 returning support group leaders, along with 31 leaders who participated for the first time. Congratulations to Robin Tuohy, IMF Vice President, Support Groups, and the entire IMF team for flawless planning and implementation. 

From the promise of immunotherapy to staying safe in the sun

At the International Myeloma Working Group (IMWG) Summit in June, the most active work group focused on immunotherapy, primarily CAR T-cell therapies and BiTEs (bi-specific T-cell engagers).